3 fast-growing biotech shares at the top of my watch list

CSL Limited (ASX:CSL) is the king of biotech shares, but could one of these three fledgling biotechs one day sit alongside it?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When it comes to Australian biotech shares there is one in particular that stands head and shoulders above the rest. That is of course the $45 billion behemoth CSL Limited (ASX: CSL).

I believe CSL is one of the highest quality companies in Australia and is thoroughly deserving of a spot in investors' portfolios.

But CSL isn't the only biotech which I feel investors should be taking a look at. At the other end of the market there are some fledgling biotech shares with potentially bright futures ahead of them. Here's why they are on my watch list:

Bionomics Ltd (ASX: BNO)

I'm very optimistic about Bionomics' BNC210 drug for the treatment of anxiety. Recent phase II trial results were promising in outperforming the current standard of care Ativan. Pleasingly BNC210 is just one of a number of drugs that Bionomics has in its pipeline. In partnership with US pharmaceutical giant Merck & Co, the company aims to bring new treatments to patients suffering from chronic pain and memory impairment. These include those with ADHD, Alzheimer's Disease, Parkinson's disease and Schizophrenia.

LBT Innovations Limited (ASX: LBT)

LBT Innovations recently announced that its Automated Plate Assessment System (APAS) has been granted approval by the US Food and Drug Administration as a Class II medical device. APAS is a revolutionary artificial intelligence technology for the automated imaging, analysis, interpretation, and reporting of growth on microbiology culture plates following incubation. Ultimately this enables the rapid diagnosis and reporting of infectious diseases to a more accurate level than a team of microbiologists, according to research published in the prestigious Journal of Clinical Microbiology.

Viralytics Ltd. (ASX: VLA)

Imagine taking that pesky common cold virus and using it to fight both melanoma and non-muscle invasive bladder cancer. Well that's exactly what Viralytics has done. CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells by enhancing the body's own defences. Although it is still early days, it is pleasing to see that so far trials have produced positive results. Should CAVATAK make it to market, analysts at Roth Capital estimate that it could command annual sales in the region of US$600 million a year.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »